Kymab victorious before UK Supreme Court in Regeneron appeal
24-06-2020
UK Supreme Court issues Warner-Lambert v Actavis ruling
14-11-2018
Kymab
Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.
Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.
In a 4-1 ruling, the Supreme Court allowed Kymab’s appeal, declaring that two of Regeneron’s patents, which cover transgenic mice, were invalid for lack of sufficient disclosure.
The requirement for sufficiency lies at the heart of this decision, said Barbara Fleck, partner at Appleyard Lees.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kymab, Regeneron, UK Supreme Court, patent sufficiency, transgenic mice, patents, biotech
